BioImpacts

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

Retrieved on: 
Tuesday, August 1, 2023
Ontario Superior Court of Justice, Share, BioImpacts, Toronto Stock Exchange, Canada Business Corporations Act, Reunion, Share (finance), Arrangement, US, TSX, DRS, MPM, Security (finance)

TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.

Key Points: 
  • TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.
  • Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive US$1.12 in cash for each Share held immediately prior to the effective time of the Arrangement.
  • With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023.
  • The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws.

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Retrieved on: 
Tuesday, July 11, 2023
BioImpacts, Biotechnology, Antibody, AstraZeneca, TCR, Novartis, Cancer, Sanofi, Eli Lilly and Company, Entrepreneurship, Therapy, MPM, Corporate development, Pharmaceutical industry, Crossbow, Polaris Partners, Merck, PMHC cellular microarray, Pfizer

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital.

Key Points: 
  • The Series A financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
  • Using proprietary technology, the company then develops TCR-mimetic antibodies with both high affinity and specificity for cancer cells.
  • “With unparalleled accuracy and potency, our revolutionary T-Bolt™ products strike cancer cells like a crossbow shoots bolts at its target.
  • Dmitri Wiederschain, Ph.D., recently joined the company as Chief Scientific Officer after previous leadership roles at Jounce Therapeutics, Sanofi, and Novartis.

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, June 29, 2023
Empyrean, Psilocybin, BioImpacts, Toronto Stock Exchange, PD, Glenmark Pharmaceuticals, D.O, Reunion, Pharmacovigilance, Biotechnology, Scientific Research and Experimental Development Tax Credit Program, Calendar, Woman, Arrangement, Bristol Myers Squibb, FAPA, Trial of the century, ASCP, Eli Lilly, Spinout, Annual general meeting, Drug discovery, TSX, Chief Medical Officer of Hungary, Johnson & Johnson, Research, Society, MPM, Scientific method, Pharmaceutical industry, Cryptocurrency

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Shareholders will be entitled to receive US$1.12 in cash for each share held immediately prior to the effective time of the take-private transaction.
  • The transaction is currently contemplated to close in the third calendar quarter of 2023, subject to satisfaction of certain closing conditions.
  • On April 3, 2023, Reunion announced that it appointed seasoned pharmaceutical executive, Fred Grossman, D.O., FAPA, to its Board of Directors.
  • Drug Effect Questionnaire and Mystical Effect Questionnaire scores observed at these dose levels indicate the potential for therapeutic effect.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRNA, CIR, REUN

Retrieved on: 
Sunday, June 11, 2023
BioImpacts, Reunion, PBC, Green-light, KKR, Sale, NYSE, Control, Advertising, Fraud, MPM, Security (finance)

If you are a GreenLight shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a GreenLight shareholder, click here to learn more about your rights and options .
  • If you are a CIRCOR shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of PRTK, CIR, REUN, and FATE

Retrieved on: 
Sunday, June 11, 2023
BioImpacts, CVR, Telephone, CIR, FATE, KKR, Sale, Destiny, Advertising, Novo Holdings A/S, MPM, Hewlett, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CIR to investment funds managed by KKR for $49.00 per share in cash.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CIR to investment funds managed by KKR for $49.00 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of REUN to affiliates of MPM BioImpact for $1.12 per share in cash.
  • If you are a FATE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PTRS, RADI, NATI, REUN

Retrieved on: 
Sunday, June 4, 2023
National Instruments, BioImpacts, Reunion, Partner, Sale, EQT, Advertising, Fraud, MPM, Security (finance)

If you are a Partners shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Partners shareholder, click here to learn more about your rights and options .
  • If you are a Radius shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

Retrieved on: 
Sunday, June 4, 2023
Telephone, GRNA, BioImpacts, AAIC, Advertising, MPM, Hewlett, Intuition, Sale, Online shopping, Security (finance)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of AAIC and Ellington Financial Inc.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of AAIC and Ellington Financial Inc.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EMBK to Applied Intuition, Inc. for $2.88 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of REUN to affiliates of MPM BioImpact for $1.12 per share in cash.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Retrieved on: 
Thursday, June 1, 2023
Psilocybin, PK, Ontario Superior Court of Justice, LLP, Share, BioImpacts, PI, Canada Business Corporations Act, Committee, Calendar, Morgan, Lewis & Bockius, Woman, Meeting, ASCP, Wilmer Cutler Pickering Hale and Dorr, Science, US, Bank, SEDAR, Annual general meeting, TSX, Oppenheimer, MPM, Society, Court, Pharmaceutical industry, Security (finance), Property management, Shareholder, Arrangement

TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has entered into a definitive arrangement agreement dated May 31, 2023 (the "Arrangement Agreement") with MPM BioImpact (“MPM”), a world-leading biotechnology investment firm, whereby affiliates of MPM would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a statutory plan of arrangement under the Canada Business Corporations Act (the "Arrangement").

Key Points: 
  • “We believe that this all-cash transaction maximizes value and is in the best interest of our shareholders,” said Greg Mayes, Reunion President and CEO.
  • Upon completion of the transaction, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM.
  • McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM.
  • The adverse event profile of RE104 was similar to that of psilocybin, with no serious adverse events.

REUN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reunion Neuroscience Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, June 1, 2023
Class Action Lawsuit, Professional Services, Legal, BioImpacts, Fraud, MPM, Advertising, Sale, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reunion Neuroscience Inc. (NASDAQ: REUN) to affiliates of MPM BioImpact for $1.12 per share in cash is fair to Reunion shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reunion Neuroscience Inc. (NASDAQ: REUN) to affiliates of MPM BioImpact for $1.12 per share in cash is fair to Reunion shareholders.
  • On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.